Observational studyMedicine2025
Analysis of risk factors for recurrence of Budd-Chiari syndrome: A retrospective study with zero-inflated model.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Systemic Inflammation Indices and Recurrence Risk in Primary Budd-Chiari Syndrome.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aims to identify an optimal model for assessing the recurrence frequency of Budd-Chiari syndrome (BCS) and further analyze the factors contributing to BCS recurrence. A total of 754 patients who were admitted to the Affiliated Hospital of Xuzhou Medical University between January 2015 and July 2022 were included. We constructed 4 different count outcome models: Poisson, negative binomial (NB) model, zero-inflated Poisson (ZIP) model, and zero-inflated negative binomial (ZINB) model. We selected the model with the best fitting performance to explore factors associated with BCS recurrence. Of 754 respondents, 511 reported no recurrence. Log-likelihood ratio tests indicated that the NB model performed better than the Poisson regression model (χ2 = 124.91, P < .001), and the ZINB model outperformed the ZIP model (χ2 = 34.29, P < .001). In the ZINB model, the analysis of the counting process revealed that the variables significantly associated with recurrence frequency included age (odds ratio [OR] = 0.69; 95% confidence interval [CI]: 0.57-0.84), sex (female: OR = 1.77; 95% CI: 1.24-2.55), anticoagulant use (warfarin vs new oral anticoagulants [NOACs]: OR = 2.11, 95% CI: 1.34-3.31; not using anticoagulants vs NOACs: OR = 1.98, 95% CI: 1.20-3.28), absence of cirrhosis (OR = 0.57, 95% CI: 0.40-0.82), and neutrophil count (NEU) (OR = 1.22, 95% CI: 1.04-1.42). The zero-inflated model proved robust in identifying factors influencing BCS recurrence compared with the other models. Influence of sex, surgery, anticoagulation, cirrhosis, hospital duration, apolipoprotein A, and NEU on the recurrence risk and frequency of BCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.